However, there have been concerns regarding possible new competitors to Botox, mainly for its therapeutic uses, which can pull down the blockbuster drug's sales in the future quarters. The entry of calcitonin gene-related peptide (CGRP) antibodies in 2018 may have a negative impact on sales of Botox for the chronic migraine indication. Amgen/Novartis, Eli Lilly ( LLY - Free Report ) and Teva Pharma's CGRP migraine treatments, Aimovig, Emgality and Ajovy, respectively were all launched in 2018.